SCHEMBL7080243

SCHEMBL7080243

CCN(C)C(=O)Oc1cccc(-c2cc(=O)c3ccccc3o2)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 6/20 0.64
ACHE P22303 3/20 0.54
TNKS O95271 3/20 0.53
PARP1 P09874 2/20 0.53
TNKS2 Q9H2K2 2/20 0.53
PLA2G2A P14555 1/20 0.51
PLA2G4A P47712 1/20 0.51
CYP3A4 P08684 2/20 0.51
HPGD P15428 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 1/20 0.51
USP2 O75604 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPK1 P28482 1/20 0.51
RECQL P46063 1/20 0.51
HSD17B10 Q99714 1/20 0.51
GABRP O00591 3/20 0.50
GABRD O14764 3/20 0.50
GABRA1 P14867 3/20 0.50
GABRB1 P18505 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7134490 0.89 TNKS (0.57) BCHEACHETNKSPARP1TNKS2
SCHEMBL7081024 0.80 BCHE (0.58) BCHEACHETNKSCYP3A4HPGD
SCHEMBL360247 0.77 CYP3A4 (0.82) TNKSPARP1TNKS2PLA2G2APLA2G4A
SCHEMBL30777197 0.77 CYP3A4 (0.82) TNKSPARP1TNKS2PLA2G2APLA2G4A
SCHEMBL7206531 0.76 CYP3A4 (0.55) CYP3A4HPGDSMN1; SMN2KDM4EUSP2
SCHEMBL7083155 0.76 CYP3A4 (0.55) TNKSCYP3A4HPGDSMN1; SMN2KDM4E
Flavone SCHEMBL22977569 0.73 TNKS (0.81) BCHEACHETNKSPARP1TNKS2
SCHEMBL10654593 0.73 CYP3A4 (0.78) TNKSPARP1TNKS2PLA2G2APLA2G4A
SCHEMBL7080450 0.72 BCHE (0.52) BCHEACHEHPGDKDM4EALDH1A1
Flavone SCHEMBL110027 0.71 TNKS (0.84) BCHEACHETNKSPARP1TNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610738-B2 Treatment of Alzheimer's Disease by combining both acetylcholinesterase inhibitory activity and antioxidant activity (by virtue of their carbamoyl and flavonoid pharmacophores) BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2003-08-26 US claimed
US-6610738-B2 Treatment of Alzheimer's Disease by combining both acetylcholinesterase inhibitory activity and antioxidant activity (by virtue of their carbamoyl and flavonoid pharmacophores) BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2003-08-26 US disclosed
EP-1322632-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES Biogal Pharmaceutical Co., Ltd (HU) 2003-07-02 EP disclosed
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2002-09-12 US disclosed
WO-2002024677-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones CBR3, FOS, CBR1 BCHE 375/4885ACHE 1755/4885TNKS 4063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.